Home/ Stocks/ SLDB

Solid Biosciences Inc. Common Stock

SLDB XNAS

$7.27 +0.23 (+3.25%) ▲ 15-min delayed

Open

$7.03

High

$7.31

Low

$7.02

Volume

924.8K

Market Cap

$715.46M

About Solid Biosciences Inc. Common Stock

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 121 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-174,325,000	$-1.99
FY 2025	$0	$-174,325,000	$-1.99
Q3 2025	$0	$-45,776,000	$-0.48
Q2 2025	$0	$-39,480,000	$-0.42

Related Market News

No specific coverage for SLDB yet. Check out our latest market news or earnings calendar.

Get SLDB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Solid Biosciences Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.